Akoya Biosciences (AKYA) said in a Wednesday filing that it received an unsolicited acquisition proposal from an undisclosed third party, which offered $1.40 in cash for each Akoya common share.
The company said its board is reviewing the proposal and has determined that it could lead to a superior proposal as defined under its merger deal with Quanterix (QTRX). Akoya said that there is no guarantee that it would constitute a superior proposal following the review.
Quanterix and Akoya Biosciences announced their updated merger agreement in April, under which Quanterix will issue about 7.76 million shares and pay $20 million in cash to Akoya shareholders.
Akoya said its board continues to recommend the merger deal with Quanterix to its shareholders.
Shares of Akoya Biosciences were up over 25% in recent Wednesday trading.
Price: 1.33, Change: +0.27, Percent Change: +25.38
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.